Introduction
============

Malignant pleural mesothelioma (MPM) is a rare but aggressive tumour of mesothelial surfaces of pleura that is mainly connected with asbestos exposure.[@b1-rado-48-02-163] Most patients are diagnosed in later stages, often with unresectable disease, therefore the prognosis is poor and median survival time is rarely above two years.[@b2-rado-48-02-163],[@b3-rado-48-02-163] Several clinical and genetic factors can have a prognostic value in MPM, but successful treatment remains challenging.[@b2-rado-48-02-163] Most patients with MPM are treated with systemic chemotherapy; usually either pemetrexed (PMX) or gemcitabine combined with a platinum agent, which are often used in different oncological diseases.[@b4-rado-48-02-163]--[@b6-rado-48-02-163] Studies have shown that chemotherapy significantly improves survival of patients with MPM. Randomized clinical trial has shown that treatment with combination of PMX and cisplatin improves outcome in patients with MPM[@b7-rado-48-02-163]--[@b9-rado-48-02-163] and comparable results were obtained for treatment with gemcitabine and cisplatin.[@b3-rado-48-02-163],[@b4-rado-48-02-163],[@b10-rado-48-02-163]

PMX is a folic acid analogue, frequently used in treatment of MPM or non-small cell lung cancer (NSCLC). It inhibits several key folate pathway enzymes, including thymidylate synthase (TYMS), thus leading to impaired DNA synthesis.[@b11-rado-48-02-163] Several other enzymes such as *MTHFD1*, *MTHFR*, *MTR*, and *MTRR*, participate in folate metabolic pathway and may influence treatment with antifolates.[@b12-rado-48-02-163]

The efficacy of PMX may also depend on its transport into and out of the cell. The most important for PMX uptake is reduced folate carrier (SLC19A1), but hepatic SLCO1B1 transporter is also involved in antifolate transport.[@b13-rado-48-02-163] On the other hand, ATP-binding cassette (ABC) transporters are involved in efflux of PMX from the cells.[@b14-rado-48-02-163],[@b15-rado-48-02-163]

Response rate to PMX treatment is up to 40% in patients with MPM[@b3-rado-48-02-163] and toxicity of PMX may be dose limiting. Differences in response to treatment with PMX may be partly due to genetic variability of enzymes involved in its transport and metabolism. Single nucleotide polymorphisms (SNPs) in folate pathway and folate transporter genes have been extensively studied regarding their impact on toxicity and efficacy of methotrexate, the most common antifolate used in chemotherapy. Regarding PMX, a newer antifolate agent, only a few studies of *TYMS*, *MTHFR*, and *SLC19A1* polymorphisms in NSCLC were published to date.[@b16-rado-48-02-163],[@b17-rado-48-02-163] Very little is known about the influence of these polymorphisms on response to treatment with PMX in MPM.[@b18-rado-48-02-163]

The aim of this study was therefore to evaluate how polymorphisms in folate pathway genes (*TYMS*, *MTHFR*, *MTHFD1*, *MTR*, *MTRR*) and transporter genes (*SLC19A1*, *SLCO1B1*, *ABCB1*, *ABCC2*, *ABCG2*) affect treatment outcome, toxicity and survival in Slovenian patients with MPM, treated with PMX.

Patients and methods
====================

Patients
--------

Patients eligible for inclusion in the pharmacogenetic study had histologically proven MPM and were participating in an ongoing prospective randomised phase II clinical trial "Cisplatin with either Alimta or Gemcitabine in long infusion (AGILI) for mesothelioma" (Trial registration ID: NCT01281800) at the Institute of Oncology Ljubljana, Slovenia.[@b19-rado-48-02-163] Patients that meet the trial's inclusion criteria were randomized in two groups, receiving either PMX or gemcitabine in combination with cisplatin.[@b19-rado-48-02-163] Patients in which cisplatin was substituted with carboplatin due to poor performance status or renal dysfunction were also included. If disease progression occurred, chemotherapy regimen was switched in second line.

Patients were diagnosed mostly at the University Clinic of Pulmonary and Allergic Diseases in Golnik, Slovenia and treated at the Institute of Oncology Ljubljana, Slovenia. Clinical data were obtained from the medical records or assessed during the clinical interview.

The study was approved by the Slovenian Ethics Committee for Research in Medicine and was carried out according to the Declaration of Helsinki.

Response, survival and toxicity assessment
------------------------------------------

Tumour response was evaluated using modified Response Evaluation Criteria in Solid Tumours (RECIST).[@b20-rado-48-02-163] Response rate was defined as the percentage of patients achieving partial or complete response. Progression-free survival (PFS) and overall survival (OS) were evaluated in survival analysis.

Haematological toxicity (anaemia, leucopoenia, neutropenia, and thrombocytopenia), liver toxicity, renal toxicity, and gastrointestinal (GI) toxicity were evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.[@b21-rado-48-02-163]

DNA extraction and genotyping
-----------------------------

Peripheral blood samples were collected before the first day of the treatment. Extraction of genomic DNA from frozen whole-blood samples was performed according to the manufacturer's instructions using Qiagen FlexiGene kit (Qiagen, Hilden, Germany).

We genotyped 19 different polymorphisms in five folate pathway and six transporter genes. *MTHFD1* rs2236225 (Arg653Gln), *MTHFR* rs1801133 (Ala222Val) and rs1801131 (Glu429Ala), *SLCO1B1* rs2306283 (Asn130Asp), and *ABCB1* rs1045642 (Ile1145Ile) polymorphisms were determined using TaqMan SNP Genotyping assays according to the manufacturer's instructions (Applied Biosystems, Foster City, CA) as previously described.[@b22-rado-48-02-163] Genotyping of *MTRR* rs1801394 (Ile22Met), *MTR* rs1805087 (Asp919Gly), *SLC19A1* rs1051266 (Arg27Cys), *SLCO1B1* rs11045879 (intronic), rs4149056 (Val174Ala) and rs2900478 (intronic), *ABCC2* rs717620 (5' untranslated region (UTR) -24C\>T), rs2273697 (Val417Ile) and rs2804402 (5' UTR -1019A\>G), *ABCC4* rs2274407 (Lys304Asn), and *ABCG2* rs2231142 (Gln141Lys) and rs2231137 (Val12Met) polymorphisms was carried out using a fluorescence-based competitive allele-specific (KASPar) assay according to the manufacturer's instructions (KBiosciences, Herts, UK). Determination of promoter *TYMS* rs34743033 (5' UTR 2R\>3R) polymorphism[@b23-rado-48-02-163] and *ABCB1* rs2032582 (Ala893Ser/Thr) polymorphism was carried out using PCR amplification followed by the analysis of PCR fragments on agarose gel as previously described.[@b24-rado-48-02-163]

Statistical analyses
--------------------

Median and range (minimum-maximum) were used to present central tendency and variability. To assess deviation from Hardy--Weinberg equilibrium (HWE), standard chi-square test was used. A dominant genetic model was used in all statistical analyses. The influences of genetic polymorphisms on treatment outcome were examined by univariable logistic regression to calculate odds ratios (ORs) and their 95% confidence intervals (CIs). In survival analysis Cox proportional hazards model was used and the hazard ratio (HR) with the 95% CI was determined. All potential clinical and treatment predictors were also independently analysed for their influence on treatment outcome. All statistical analyses were carried out by Statistical Package for the Social Sciences (SPSS) for Windows, version 19.0 (IBM Corporation, Armonk, NY, USA).

Haplotypes were reconstructed and analysed using Thesias software[@b25-rado-48-02-163] as described previously.[@b26-rado-48-02-163] Only haplotypes with frequencies above 5% were included in the statistical analyses and the most frequent haplotype was used as reference.

All statistical tests were two-sided and the level of significance was set to 0.05. Due to the exploratory nature of the study, no adjustments for multiple comparisons were used.

Results
=======

Patients' characteristics
-------------------------

In our study, we included 41 patients with MPM, participating in the AGILI trial from 2008 to December 2012. In total, 29 patients received PMX as first line of chemotherapy and 12 received PMX as second line. Clinical characteristics of the study group are summarized in [Table 1](#t1-rado-48-02-163){ref-type="table"}. Twenty (48.8%) patients were smokers and 33 (80.5%) were either occupationally or environmentally exposed to asbestos. Median C-reactive protein (CRP) level at diagnosis was 23 mg/l (range: 1−192 mg/l). The majority of patients (70.7%) received at least 4 cycles of chemotherapy. To the date of the analysis, disease progression occurred in 32 (78.0%) patients and 23 patients (56.1%) had died. There were no significant differences between patients receiving PMX as the first or second line of chemotherapy ([Table 1](#t1-rado-48-02-163){ref-type="table"}).

Genotyping analysis
-------------------

All genotype frequencies ([Supplemental Table 1](#SD1){ref-type="supplementary-material"}) were in agreement with HWE (*p* \> 0.05). Three SNPs were excluded from further statistical analyses: *SLCO1B1* rs2900478 was in complete linkage disequilibrium (LD) with *SLCO1B1* rs11045879, while *ABCG2* rs2231137 and *ABCC4* rs2274407 were too rare.

Tumour response analysis
------------------------

Among 41 patients, one (2.4%) was a complete responder and 12 (29.3%) were partial responders, meaning the overall response rate was 31.7%. Nineteen patients had stable disease and nine had progressive disease. Data on the influence of polymorphisms on response rate are presented in [Table 2](#t2-rado-48-02-163){ref-type="table"}. Patients with at least one polymorphic *MTHFD1* rs2236225 allele had lower response rate (*p* = 0.005; OR = 0.12; 95% CI = 0.03−0.54) than patients with two wild-type alleles. On the other hand, patients with at least one polymorphic *ABCC2* rs2273697 had significantly better response rate than non-carriers (*p* = 0.031; OR = 4.75; 95% CI = 1.15−19.65).

Higher TNM stage was the only clinical parameter significantly associated with lower response rate (*p* = 0.013; OR = 0.35; 95% CI = 0.15−0.79). After adjustment for TNM stage, *MTHFD1* rs2236225 remained associated with response rate (*p* = 0.016; OR = 0.14; 95% CI = 0.03−0.70), but the effect of *ABCC2* rs2273697 was no longer significant (*p* = 0.065; OR = 4.32; 95% CI = 0.91−20.43).

Toxicity analysis
-----------------

Several polymorphisms in transporter genes influenced occurrence of treatment-related toxicities. *ABCC2* rs2273697 conferred protection against development of any toxicity (*p* = 0.035; OR = 0.09; 95% CI = 0.01−0.85). Liver toxicity was significantly less frequent in carriers of polymorphic *SLCO1B1* rs11045879 (*p* = 0.014; OR = 0.18; 95% CI = 0.05−0.71) and rs4149056 (*p* = 0.028; OR = 0.23; 95% CI = 0.06−0.85) alleles. *ABCC2* rs2273697 was also associated with decreased liver toxicity (*p* = 0.028; OR = 0.23; 95% CI = 0.06−0.85). On the other hand, GI toxicity was much more common in patients with polymorphic *ABCC2* rs717620 allele (*p* = 0.004; OR = 10.67; 95% CI = 2.15--52.85). The other investigated polymorphisms in transporter and folate pathway genes did not significantly affect occurrence of either overall or specific toxicity ([Table 3](#t3-rado-48-02-163){ref-type="table"} and [Supplemental Table 2](#SD2){ref-type="supplementary-material"}).

Survival analysis
-----------------

Analysis of OS was performed in the whole cohort of patients, while PFS was only analysed in the group of patients receiving PMX in the first line treatment. Firstly, clinical and treatment characteristics were examined for their influence on PFS or OS. Increased level of CRP before the first day of the treatment was the only parameter associated both with shorter PFS and shorter OS (*p* = 0.002, HR = 1.015, 95% CI = 1.01−1.03 and *p* \< 0.001, HR = 1.015, 95% CI = 1.01−1.02, respectively). Patients with sarcomatoid or biphasic MPM had significantly shorter PFS (*p* = 0.026, HR = 4.59, 95% CI = 1.20−17.52). On the other hand, if patients received more chemotherapy cycles, OS was longer (*p* = 0.024, HR = 0.36, 95% CI = 0.15−0.88). However, only CRP remained significant in multivariable model.

The data on the influence of SNPs on survival is presented in [Table 2](#t2-rado-48-02-163){ref-type="table"}. Among the investigated polymorphisms, only *MTHFD1* rs2236225 significantly influenced PFS (*p* = 0.032; HR = 3.10; 95% CI = 1.10−8.74) after adjustment for CRP level ([Figure 1](#f1-rado-48-02-163){ref-type="fig"}). MPM patients with at least one polymorphic *MTHFD1* allele and high CRP level had shorter survival than patients with two wild-type alleles and lower CRP level.

Haplotype analysis
------------------

Haplotype analysis was performed to assess the combined effect of SNPs within one gene. Three *SLCO1B1* haplotypes (ATT, GCC, and GTT) had frequencies above 5% and covered approximately 98% of variability within this gene ([Table 4](#t4-rado-48-02-163){ref-type="table"}). Liver toxicity was less common in patients with GCC haplotype. This haplotype included all the polymorphic alleles, associated with decreased liver toxicity in single SNP analysis, compared with the reference ATT haplotype (*p* = 0.048; OR = 0.17; 95% CI = 0.03−0.98).

Four *ABCC2* haplotypes (CGG, CAG, TGG and TGA) covered all the variability within this gene ([Table 4](#t4-rado-48-02-163){ref-type="table"}). GI toxicity was significantly more common in patients with CAG haplotype (*p* = 0.006; OR = 5.67; 95% CI = 1.64−19.66) with polymorphic rs717620 allele, associated with increased GI toxicity in single SNP analysis.

Discussion
==========

Patients with MPM participating in a prospective randomized clinical trial were investigated for the influence of folate pathway and transporter polymorphisms on PMX treatment response. Among folate pathway genes only *MTHFD1* was associated with response rate and survival, while transporters mainly influenced PMX-related toxicity.

Only few pharmacogenetic studies on PMX treatment have been published so far. The only study in MPM focused on *TYMS* rs34743033, a tandem repeat of 28 base pairs in the 5′ UTR promoter region that changes TYMS mRNA and protein expression.[@b18-rado-48-02-163] Consistent with our results, no association of this polymorphism with treatment outcome was observed, even though both mRNA and protein expression significantly affected survival.[@b18-rado-48-02-163],[@b27-rado-48-02-163],[@b28-rado-48-02-163] Similar results were obtained in NSCLC.[@b17-rado-48-02-163],[@b29-rado-48-02-163]--[@b32-rado-48-02-163]

In our study, the carriers of the polymorphic *MTHFD1* rs2236225 allele had a significantly shorter PFS and were less likely to achieve complete or partial response, even after adjustment for TNM stage. MTHFD1 is essential for the generation of methylene-THF required for thymidylate synthesis and *MTHFD1* rs2236225 (Arg653Gln) was shown to reduce the enzyme activity[@b33-rado-48-02-163], leading to increased levels of methylene-THF and reducing cytotoxic effects of PMX.[@b23-rado-48-02-163],[@b34-rado-48-02-163] To our knowledge, no previous studies investigated the role of *MTHFD1* SNPs in treatment with PMX. However, in some, but not all studies on methotrexate treatment in acute lymphoblastic leukaemia (ALL), the variant allele was associated with shorter event-free survival.[@b23-rado-48-02-163],[@b34-rado-48-02-163]

In our MPM patients PMX treatment outcome was not influenced by other investigated folate pathway SNPs. Most of them have not been studied yet in PMX treated MPM patients, however in NSCLC polymorphic *MTHFR* rs1801133 allele conferred to increased survival in a recessive model.[@b17-rado-48-02-163],[@b31-rado-48-02-163]

To our knowledge, this is the first study investigating folate transporter gene polymorphisms regarding treatment outcome in MPM. Patients with at least one polymorphic *ABCC2* rs2273697 allele had better response rate and less overall and liver toxicity than non-carriers, while polymorphic *ABCC2* rs717620 allele and *ABCC2* CAG haplotype conferred to increased GI toxicity. *ABCC2* encodes one of the multidrug resistance associated transporters, involved in transport of both natural folates and antifolate agents.[@b35-rado-48-02-163] The knowledge about the functional significance of *ABCC2* SNPs is limited, but rs717620 was associated with decreased promoter activity and mRNA expression of *ABCC2*, possibly affecting the accumulation of PMX in cells.[@b15-rado-48-02-163],[@b36-rado-48-02-163] However, *ABCC2* is also involved in transport of platinum compounds and this could contribute to its effect on treatment response. Indeed, some studies have shown that rs717620 affects treatment with platinum agents in lung cancer.[@b37-rado-48-02-163],[@b38-rado-48-02-163]

In the present study, polymorphic *SLCO1B1* rs11045879 and rs4149056 alleles were significantly associated with liver toxicity both in single SNP and haplotype analysis. *SLCO1B1* encodes one of the main influx transporters expressed on the basolateral membrane of hepatocytes involved in uptake and clearance of many endogenous compounds and drugs, such as methotrexate.[@b39-rado-48-02-163] *SLCO1B1* rs4149056 and rs2306283 were associated with decreased membrane expression and activity of the transporter.[@b39-rado-48-02-163],[@b40-rado-48-02-163] Rs11045879 was identified in a genome-wide association study as the most important genetic factor associated with lower methotrexate clearance in patients with ALL. In later studies, a similar association with methotrexate clearance was observed for rs4149056.[@b40-rado-48-02-163],[@b41-rado-48-02-163]

Although *SLC19A1* is the predominant uptake transporter for antifolates, we observed no impact of rs1051266 on PMX treatment. Our results are consistent with studies on NSCLC[@b17-rado-48-02-163],[@b31-rado-48-02-163], although one study reported several other *SLC19A1* SNPs associated with OS.[@b16-rado-48-02-163]

Our study represents the first comprehensive pharmacogenetic study of treatment with PMX in MPM patients participating in a prospective randomized trial. As MPM is a rare cancer, some potential limitations of our study arise from its small sample size, such as low statistical power. However, the strength of our study was that all patients were from a homogenous population[@b42-rado-48-02-163], included in phase II clinical trial with well-defined inclusion criteria and clinical protocol, and treated in the same facility, thus minimizing the impact of other variables. We also evaluated the influence of potentially important clinical parameters and included haplotype analysis to evaluate the combined influence of more SNPs in one gene.

Both PMX and gemcitabine have shown comparable efficacy in MPM treatment.[@b3-rado-48-02-163],[@b4-rado-48-02-163] In previous studies, we have identified some polymorphisms that influence MPM treatment with gemcitabine and cisplatin.[@b26-rado-48-02-163],[@b43-rado-48-02-163],[@b44-rado-48-02-163] Our present results show for the first time that *MTHFD1*, *ABCC2*, and *SLCO1B1* polymorphisms may play an important role in PMX treatment response in patients with MPM. These SNPs could serve as biomarkers for more personalized treatment and in the future, selection of treatment based on genetic factors may contribute to better treatment outcomes in patients with MPM.
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###### 

Clinical and treatment characteristics of patients with malignant pleural mesothelioma receiving pemetrexed (PMX) chemotherapy

  **Characteristic**                                 **All patients (N = 41)**   **PMX first line (N = 29)**   **PMX second line (N = 12)**   **p**
  ------------------------------- ------------------ --------------------------- ----------------------------- ------------------------------ -------------------------------------------------------
  **Gender**                      Male               33 (80.5)                   22 (75.9)                     11 (91.7)                      0.398[^a^](#tfn1-rado-48-02-163){ref-type="table-fn"}
  Female                          8 (19.5)           7 (24.1)                    1 (8.3)                                                      
  **Stage**                       I                  3 (7.3)                     3 (10.3)                      0                              0.578[^a^](#tfn1-rado-48-02-163){ref-type="table-fn"}
  II                              12 (29.3)          9 (31.0)                    3 (25.0)                                                     
  III                             12 (29.3)          9 (31.0)                    3 (25.0)                                                     
  IV                              14 (34.1)          8 (27.6)                    6 (50.0)                                                     
  **Histological type**           Epitheloid         33 (80.5)                   25 (86.2)                     8 (66.7)                       0.267[^a^](#tfn1-rado-48-02-163){ref-type="table-fn"}
  Biphasic                        3 (7.3)            1 (3.4)                     2 (16.7)                                                     
  Sarcomatoid                     3 (7.3)            2 (6.9)                     1 (8.3)                                                      
  Not characterized               2 (4.9)            1 (3.4)                     1 (8.3)                                                      
  **ECOG performance status**     0                  20 (48.8)                   15 (51.7)                     5 (41.7)                       0.499[^a^](#tfn1-rado-48-02-163){ref-type="table-fn"}
  1                               18 (43.9)          11 (37.9)                   7 (58.3)                                                     
  2                               3 (7.3)            3 (10.3)                    0                                                            
  **Response rate**               CR and PR          13 (31.7)                   11 (37.9)                     2 (16.7)                       0.140[^a^](#tfn1-rado-48-02-163){ref-type="table-fn"}
  SD                              19 (46.3)          14 (48.3)                   5 (41.7)                                                     
  Progress                        9 (22.0)           4 (13.8)                    5 (41.7)                                                     
  **Liver toxicity**              Present            24 (58.5)                   15 (51.7)                     9 (75.0)                       0.296[^a^](#tfn1-rado-48-02-163){ref-type="table-fn"}
  Absent                          17 (41.5)          14 (48.3)                   3 (25.0)                                                     
  **GI toxicity**                 Present            11 (26.8)                   9 (31.0)                      2 (16.7)                       0.457[^a^](#tfn1-rado-48-02-163){ref-type="table-fn"}
  Absent                          30 (73.2)          20 (69.0)                   10 (83.3)                                                    
  **Haematological toxicity**     Present            19 (46.3)                   13 (44.8)                     6 (50.0)                       1.000[^a^](#tfn1-rado-48-02-163){ref-type="table-fn"}
  Absent                          22 (53.7)          16 (55.2)                   6 (50.0)                                                     
  **Renal toxicity**              Present            18 (43.9)                   13 (44.8)                     5 (41.7)                       1.000[^a^](#tfn1-rado-48-02-163){ref-type="table-fn"}
  Absent                          23 (56.1)          16 (55.2)                   7(58.3)                                                      
  **Overall toxicity**            Present            34 (82.9)                   23 (79.3)                     11 (91.7)                      0.419[^a^](#tfn1-rado-48-02-163){ref-type="table-fn"}
  Absent                          7 (17.1)           6 (20.7)                    1 (8.3)                                                      
  **Overall survival**            median (min-max)   12.1 (1.0--36.1)            11.9 (1.0--36.1)              14.4 (6.4--31.6)               0.558[^b^](#tfn2-rado-48-02-163){ref-type="table-fn"}
  **Progression-free survival**   median (min-max)   6.5 (1.0--36.1)             6.7 (1.0--36.1)               6.4 (6.4--31.6)                0.431[^b^](#tfn2-rado-48-02-163){ref-type="table-fn"}
  **Age**                         median (min-max)   63 (35--79)                 63 (35--79)                   64 (46--78)                    0.785[^b^](#tfn2-rado-48-02-163){ref-type="table-fn"}

calculated using Fisher's exact test;

calculated using Mann-Whitney U-test; CR = complete response; PR = partial response; SD = stable disease; ECOG = Eastern Cooperative Oncology Group; GI = gastrointestinal

###### 

The influence of investigated polymorphisms on response rate, overall survival (N = 41) and progression-free survival (N = 29) in patients with malignant pleural mesothelioma

  **Gene**        **Polymorphism**                 **Response rate[^a^](#tfn3-rado-48-02-163){ref-type="table-fn"}**   **Progression-free survival[^b^](#tfn4-rado-48-02-163){ref-type="table-fn"}**   **Overall survival[^b^](#tfn4-rado-48-02-163){ref-type="table-fn"}**                           
  --------------- -------------------- ----------- ------------------------------------------------------------------- ------------------------------------------------------------------------------- ---------------------------------------------------------------------- ----------- ----------- --
  ***MTHFR***     rs1801133            CC          Reference                                                                                                                                           Reference                                                                          Reference   
  CT+TT           0.63 (0.16--2.39)    0.492       1.82 (0.69--5.04)                                                   0.248                                                                           1.11 (0.47--2.64)                                                      0.809                   
  rs1801131       AA                   Reference                                                                       Reference                                                                                                                                              Reference               
  AC+CC           0.76 (0.20--2.85)    0.678       0.93 (0.37--2.34)                                                   0.880                                                                           1.15 (0.49--2.74)                                                      0.746                   
  ***MTHFD1***    rs2236225            GG          Reference                                                                                                                                           Reference                                                                          Reference   
  GA+AA           0.12 (0.03--0.54)    **0.005**   3.10 (1.10--8.74)                                                   **0.032**                                                                       1.81 (0.72--4.57)                                                      0.207                   
  ***TYMS***      rs34743033           2R/2R       Reference                                                                                                                                           Reference                                                                          Reference   
  2R/3R+3R/3R     0.47 (0.12--1.83)    0.274       0.77 (0.28--2.08)                                                   0.605                                                                           0.62 (0.23--1.66)                                                      0.336                   
  ***MTRR***      rs1801394            AA          Reference                                                                                                                                           Reference                                                                          Reference   
  AG+GG           0.91 (0.19--4.39)    0.906       1.14 (0.31--4.20)                                                   0.841                                                                           0.57 (0.18--1.78)                                                      0.334                   
  ***MTR***       rs1805087            AA          Reference                                                                                                                                           Reference                                                                          Reference   
  AG+GG           0.97 (0.25--3.73)    0.960       1.38 (0.57--3.32)                                                   0.473                                                                           1.57 (0.66--3.72)                                                      0.310                   
  ***SLC19A1***   rs1051266            GG          Reference                                                                                                                                           Reference                                                                          Reference   
  GA+AA           0.90 (0.21--3.78)    0.886       1.05 (0.35--3.17)                                                   0.925                                                                           1.45 (0.57--3.69)                                                      0.437                   
  ***SLCO1B1***   rs2306283            AA          Reference                                                                                                                                           Reference                                                                          Reference   
  AG+GG           1.33 (0.29--6.15)    0.712       1.12 (0.44--2.89)                                                   0.809                                                                           1.75 (0.65--4.69)                                                      0.265                   
  rs4149056       TT                   Reference                                                                       Reference                                                                                                                                              Reference               
  TC+CC           0.72 (0.19--2.76)    0.633       0.65 (0.27--1.60)                                                   0.348                                                                           0.83 (0.35--1.94)                                                      0.664                   
  rs11045879      TT                   Reference                                                                       Reference                                                                                                                                              Reference               
  TC+CC           0.83 (0.22--3.20)    0.790       0.63 (0.26--1.53)                                                   0.306                                                                           0.86 (0.37--2.01)                                                      0.724                   
  ***ABCB1***     rs2032582            GG          Reference                                                                                                                                           Reference                                                                          Reference   
  GT+GA+TT+AA     0.49 (0.11--2.25)    0.358       2.89 (0.62--13.44)                                                  0.177                                                                           1.47 (0.54--4.01)                                                      0.448                   
  rs1045642       CC                   Reference                                                                       Reference                                                                                                                                              Reference               
  CT+TT           0.92 (0.15--5.78)    0.926       3.19 (0.40--25.62)                                                  0.275                                                                           3.90 (0.50--30.26)                                                     0.193                   
  ***ABCC2***     rs2804402            CC          Reference                                                                                                                                           Reference                                                                          Reference   
  CT+TT           1.83 (0.32--10.37)   0.493       0.57 (0.18--1.81)                                                   0.338                                                                           0.99 (0.34--2.90)                                                      0.987                   
  rs717620        GG                   Reference                                                                       Reference                                                                                                                                              Reference               
  GA+AA           0.46 (0.10--2.07)    0.314       2.08 (0.75--5.79)                                                   0.159                                                                           1.10 (0.46--2.64)                                                      0.826                   
  rs2273697       GG                   Reference                                                                       Reference                                                                                                                                              Reference               
  GA+AA           4.75 (1.15--19.65)   **0.031**   0.57 (0.22--1.49)                                                   0.252                                                                           0.88 (0.37--2.08)                                                      0.763                   
  ***ABCG2***     rs2231142            CC          Reference                                                                                                                                           Reference                                                                          Reference   
  CA+AA           2.29 (0.55--9.64)    0.258       2.13 (0.65--6.94)                                                   0.209                                                                           1.57 (0.60--4.11)                                                      0.361                   

calculated using logistic regression;

calculated by Cox proportional hazards model and adjusted for C-reactive protein level

###### 

The influence of investigated polymorphisms on liver and gastrointestinal (GI) toxicity (N = 41)

  **Gene**        **Polymorphism**                       **Liver toxicity[^a^](#tfn5-rado-48-02-163){ref-type="table-fn"}**   **GI toxicity[^a^](#tfn5-rado-48-02-163){ref-type="table-fn"}**                                                                                             
  --------------- ------------------ ------------------- -------------------------------------------------------------------- ----------------------------------------------------------------- --------------------- ------------------------------------------------------- ----------- --
  ***MTHFR***     rs1801133          CC                  10 (45.5)                                                            Reference                                                                               6 (27.3)                                                Reference   
  CT+TT           14 (73.7)          3.37 (0.90--12.6)   0.072                                                                5 (26.3)                                                          0.95 (0.24--3.81)     0.945                                                               
  rs1801131       AA                 10 (58.8)           Reference                                                                                                                              5 (29.4)              Reference                                                           
  AC+CC           14 (58.3)          0.98 (0.28--3.46)   0.975                                                                6 (25.0)                                                          0.80 (0.20--3.22)     0.754                                                               
  ***MTHFD1***    rs2236225          GG                  7 (46.7)                                                             Reference                                                                               5 (33.3)                                                Reference   
  GA+AA           17 (65.4)          2.16 (0.59--7.90)   0.245                                                                6 (23.1)                                                          0.60 (0.15--2.46)     0.477                                                               
  ***TYMS***      rs34743033         2R/2R               7 (50.0)                                                             Reference                                                                               2 (14.3)                                                Reference   
  2R/3R+3R/3R     17 (63.0)          1.7 (0.46--6.28)    0.426                                                                9 (33.3)                                                          3.00 (0.55--16.38)    0.205                                                               
  ***MTRR***      rs1801394          AA                  6 (66.7)                                                             Reference                                                                               1 (11.1)                                                Reference   
  AG+GG           18 (56.3)          0.64 (0.14--3.04)   0.577                                                                10 (31.3)                                                         3.64 (0.40--33.12)    0.252                                                               
  ***MTR***       rs1805087          AA                  15 (60.0)                                                            Reference                                                                               5 (20.0)                                                Reference   
  AG+GG           9 (56.3)           0.86 (0.24--3.06)   0.812                                                                6 (37.5)                                                          2.40 (0.59--9.82)     0.223                                                               
  ***SLC19A1***   rs1051266          GG                  6 (50.0)                                                             Reference                                                                               4 (33.3)                                                Reference   
  GA+AA           18 (62.1)          1.64 (0.42--6.36)   0.477                                                                7 (24.1)                                                          0.64 (0.15--2.77)     0.547                                                               
  ***SLCO1B1***   rs2306283          AA                  9 (81.8)                                                             Reference                                                                               3 (27.3)                                                Reference   
  AG+GG           15 (50.0)          0.22 (0.04--1.21)   0.081                                                                8 (26.7)                                                          0.97 (0.21--4.59)     0.696                                                               
  rs4149056       TT                 17 (73.9)           Reference                                                                                                                              4 (17.4)              Reference                                                           
  TC+CC           7 (38.9)           0.23 (0.06--0.85)   **0.028**                                                            7 (38.9)                                                          3.02 (0.72--12.70)    0.131                                                               
  rs11045879      TT                 18 (75.0)           Reference                                                                                                                              5 (20.8)              Reference                                                           
  TC+CC           6 (35.3)           0.18 (0.05--0.71)   **0.014**                                                            6 (35.3)                                                          2.07 (0.51--8.41)     0.308                                                               
  ***ABCB1***     rs2032582          GG                  5 (55.6)                                                             Reference                                                                               2 (22.2)                                                Reference   
  GT+GA+TT+AA     19 (59.4)          1.17 (0.26--5.20)   0.837                                                                9 (28.1)                                                          1.37 (0.24--7.88)     0.725                                                               
  rs1045642       CC                 6 (66.7)            Reference                                                                                                                              0 (0.0)               Reference                                                           
  CT+TT           20 (57.1)          0.67 (0.11--4.13)   0.663                                                                11 (31.4)                                                         /                     0.167[^b^](#tfn6-rado-48-02-163){ref-type="table-fn"}               
  ***ABCC2***     rs2804402          CC                  8 (88.9)                                                             Reference                                                                               3 (33.3)                                                Reference   
  CT+TT           16 (50.0)          0.13 (0.01--1.12)   0.063                                                                8 (25.0)                                                          0.67 (0.14--3.30)     0.619                                                               
  rs717620        GG                 15 (55.6)           Reference                                                                                                                              3 (11.1)              Reference                                                           
  GA+AA           9 (64.3)           1.44 (0.38--5.45)   0.591                                                                8 (57.1)                                                          10.67 (2.15--52.85)   **0.004**                                                           
  rs2273697       GG                 17 (73.9)           Reference                                                                                                                              6 (26.31)             Reference                                                           
  GA+AA           7 (38.9)           0.23 (0.06--0.85)   **0.028**                                                            5 (27.8)                                                          1.09 (0.27--4.37)     0.903                                                               
  ***ABCG2***     rs2231142          CC                  17 (56.7)                                                            Reference                                                                               10 (33.3)                                               Reference   
  CA+AA           7 (63.6)           1.34 (0.32--5.56)   0.689                                                                1 (9.1)                                                           0.20 (0.02--1.79)     0.150                                                               

calculated using logistic regression;

calculated using Fisher's exact test as there were no patients in one group

###### 

The influence of *SLCO1B1* and *ABCC2* haplotypes on response rate, gastrointestinal (GI), and liver toxicity (N = 41)

  **Gene**        **Haplotype**   **Estimated frequency**   **Response rate**   **GI toxicity**      **Liver toxicity**                       
  --------------- --------------- ------------------------- ------------------- -------------------- -------------------- ------------------- -----------
  ***SLCO1B1***   ATT             0.47                      Reference           Reference            Reference                                
  GCC             0.22            0.98 (0.24--4.04)         0.973               2.63 (0.61--11.37)   0.195                0.17 (0.03--0.98)   **0.048**
  GTT             0.29            1.94 (0.66--5.74)         0.229               0.37 (0.07--1.93)    0.237                0.46 (0.13--1.63)   0.230
  ***ABCC2***     CGG             0.28                      Reference           Reference            Reference                                
  CAG             0.20            0.30 (0.05--1.71)         0.175               5.67 (1.64--19.66)   **0.006**            1.06 (0.21--5.05)   0.941
  TGG             0.28            0.29 (0.06--1.46)         0.133               0.33 (0.07--1.61)    0.171                0.74 (0.18--3.07)   0.680
  TGA             0.24            1.59 (0.39--6.43)         0.519               0.88 (0.23--3.39)    0.847                0.29 (0.06--1.27)   0.099
